COLLABORATION AND LICENSE AGREEMENT by and between ALNYLAM PHARMACEUTICALS, INC. on the one hand and F. Hoffmann-La Roche Ltd. and Genentech, Inc. on the other hand. EFFECTIVE DATE: July 21, 2023Collaboration and License Agreement • November 2nd, 2023 • Alnylam Pharmaceuticals, Inc. • Pharmaceutical preparations
This COLLABORATION AND LICENSE AGREEMENT (this “Agreement”) is entered into as of July 21, 2023 (the “Effective Date”) by and between ALNYLAM PHARMACEUTICALS, INC., a Delaware corporation having its principal place of business at 675 West Kendall Street, Cambridge, Massachusetts 02142 USA (“Alnylam”), on the one hand, and F. HOFFMANN-LA ROCHE LTD., having an office and place of business at Grenzacherstrasse 124, 4070 Basel, Switzerland (“Roche Basel”) and GENENTECH, INC., with an office and place of business at 1 DNA Way, South San Francisco, California 94080, (“Genentech”; each of Roche Basel and Genentech individually and collectively, “Roche”), on the other hand. Alnylam and Roche are sometimes referred to herein individually as a “Party” and collectively as the “Parties.”
